 | Related Articles |
Immunotherapy and Radiation: Charting a Path Forward Together.
Hematol Oncol Clin North Am. 2019 Dec;33(6):1057-1069
Authors: Sridharan V, Schoenfeld JD
Abstract
Preclinical studies combining immunotherapy and radiation therapy have suggested promising synergy, prompting translation into clinical trials. Radiation has been shown to significantly alter the tumor microenvironment, cause immunogenic cell death, and potentiate anti-tumor immune responses. Several radiation parameters may modulate these effects. Clinical data to date have suggested that combination therapy is largely well tolerated, but additional study is warranted to better estimate both short-term and long-term risks of combination treatment and extend these data to new immunotherapy agents. Ensuring proper radiation access and quality is critical to the success of future trials.
PMID: 31668206 [PubMed - in process]